Foxp3 expressing regulatory T-cells in allergic disease

Advances in Experimental Medicine and Biology

Volumn 665, Issue , 2009, Pages 180-193

  Nouri Aria, Kayhan T ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; COLECALCIFEROL; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DEXAMETHASONE; GLUCOCORTICOID; HYMENOPTERA VENOM; INTERLEUKIN 10; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN;

ADOPTIVE TRANSFER; ALLERGIC ASTHMA; ALLERGIC DISEASE; ALLERGIC RHINITIS; ARTICLE; ATOPIC DERMATITIS; ATOPY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ CD25+ T LYMPHOCYTE; CONJUNCTIVITIS; GRAFT REJECTION; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INSECT ALLERGY; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; ANIMAL; ASTHMA; IMMUNOLOGY; METABOLISM; REVIEW; RHINITIS;

ANIMALS; ASTHMA; AUTOIMMUNE DISEASES; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; RHINITIS; T-LYMPHOCYTES, REGULATORY;

EID: 77952510797     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-1599-3_14     Document Type: Article

References (89)

1. SakaguchiS. Sakaguchi N. AsanoM, et al. Immunologic self-tolerance maintained by activated'f-cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes variousautoimmune diseases. J Immunol 1995; 155:1151-1164.
2. AsanoM. Toda M. Sakaguchi N, et al. Autoimmune disease as a consequence of developmental abnormality of a Tvcell subpopulation. J Exp Med 1996; 184:387-396. (Pubitemid 26324092)
3. Ng WF. Duggan PJ, Ponchel F, et al. Human CD4+CD25+ cells: A naturally occurring population of regulatoryT-cells. Blood 2001; 98:2736-2744.
4. jonuleir H. Schmitt E. Stassen M, et al. Identification and functional characterization of human CD4+CD25+Tvcells with regulatory properties isolated from peripheral blood. J Exp Med 2001; 193:1285-1294. (Pubitemid 32524778)
5. Dieckmann D. Plotrner H. Berchtold S, et al. Ex vivo isolation and characterization of CD4+CD25+ Tvcells with regulatory properties from human blood. J Exp Med 2001; 193:1303-1310. (Pubitemid 32524780)
6. Levings MK, Sangregorio R. Roncarolo MG. Human CD25+CD4+ T regulatory cellssuppress naive and memory 'Tcell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001; 193:1295-1302.
7. Thornton AM. Shevach EM. CD4+CD25+ immunoregulatory T-cellssuppress polyclonal T-cell activation in vitro by inhibiting inrerleukin 2 production. J Exp Med 1998; 188:287-296. (Pubitemid 28357757)
8. Bayet al. YuA. Adeegbe O, et al. Essential role for interleukin-Z for CD4+CD25+ T regulatory cell developmentduring the neonatal period.J Exp Med 2005; 201:769-777. (Pubitemid 40403028)
9. Read S. Malmstrom V. Powrie F. Cytotoxic T-Iymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regularory cells that control intestinal inflammation. J Exp Med 2000; 19:295-302. (Pubitemid 30470312)
10. Graca L. Honey K. AdamsE, et al. Cutting edge: Anti-CDl54 therapeutic antibodies induce infectious transplantation tolerance. J Immunol 2000; 165:4783-4786.
11. McHugh RS. Whitters MJ. Piccirillo CA, et al. CD4+CD25+immunoregularory T-cells: Gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002; 1:311-323. (Pubitemid 34211969)
12. Liu W; Putnam AL. Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+Treg cells. J Exp Med 2006; 203:1701-1711. (Pubitemid 44036276)
13. Nouri-Aria KT. Durham SR. Regulatory Tvcells and allergic disease. Inflamm Allergy Drug Targets 2008; 7:237-52. Review.
14. Hori S. Nomura T. Sakaguchi S. Control of regulatoryT-cell development by the transcription factor Foxp3. Science 2003; 299:1057-1061. (Pubitemid 36222930)
15. Fonrcnotj D, GavinMA. Rudensky AY. Foxp3programsthe development and function ofCD4+CD2S+ regulatory T-cells. Nat Immunol 2003; 4:330-336. (Pubitemid 36432314)
16. Brandenburg S.Takahashi T. de la Rosa M, et al. IL-2 induces in vivosuppression by CD4+CD2S+Foxp3+ regulatory T-cells. Eur J Immunol 2008; 38:1643-1653.
17. Lin W; Haribhai D. Relland LM, et al. Regulatory T-cell development in the absence of functional Foxp3. Nat Immunol 2007; 8:359-368. (Pubitemid 46745411)
18. Khattri R. Cox T. Yasayko SA, et al. An essential role for Scur6n in CD4+CD25+ T regulatory cells. Nat Immunol 2003; 4:337-342. (Pubitemid 36432315)
19. Bennett CL. Christie J. Ramsdell F, et al. The immunedysregulation, polyendocrinopathy. enteropathy. X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001; 27:20-21. (Pubitemid 32044513)
20. Yagi H. Nomura T. Nakamura K, et al. Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatoryT. Int Immunol 2004; 16:1643-1656.
21. Ziegler SF. FOXP3: Of mice and men. Annu Rev Immunol 2006; 24:209-226. Review.
22. Schmidt-Weber CB. Blaser K. The role of the FOXP3 transcription factor in the immune regulationof allergic asthma. Curr Allergy Asthma Rep 2005; 5:356-361. (Pubitemid 41683978)
23. Mantel PY. Ouaked N. RuckertBet al. Molecularmechanisms underlyingFOXP3 induction in human T-cells. J Immunol 2006; 176:3593-3602. (Pubitemid 43364007)
24. Zorn E. NelsonEA. MohseniM, et al. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory Tvcells through a STATdependent mechanism and induces the expansion of these cells in vivo. Blood 2006; 108:1571-1579. (Pubitemid 44316124)
25. Fontenot JD. Rasmussen JP. Gavin MA, et al. A function for interleukin 2 in Foxp3-expressing regulatory T-cells. Nat Immunol 2005; 6:1142-1151. (Pubitemid 41541792)
26. Janson PC, Winerdal ME, Marits P, et al. FOXP3 promoter demerhylarion reveals the committed Treg population in humans. PLoS ONE 2008; 3:e1612.
27. Allan SE, Song-Zhao GX. Abraham T, et al. Inducible reprogramming of human T-cdls into Treg cells by a conditionally active form of FOXP3. Eur J Immunol2008; 38:3282-3289.
28. Bardd E. Larousserie F, Charlot-Rabiega P. Human CD4+CD25+Foxp3+ regulatory T-cells do not constitutively express IL-35. J Immunol 2008; 181:6898-6905
29. Collison LW; Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cdl function Nature 2007; 450:566-569. (Pubitemid 350190247)
30. Cottrez F, Hurst SD, Collinan RL, et al. T regulatory cells 1 inh ibit a Th2-specific response in vivo. J Immunol 2000; 165:4848-4853
31. Akdis M. VerhagenJ, Taylor A, et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004; 199:1567-1575. (Pubitemid 38780411)
32. Ling EM, Smith T. Dao Nguyen X, et al. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004; 363:608-615 (Pubitemid 38264178)
33. Karlsson MR. Rugrveit J. Brandrzaeg P. Allergen-responsive CD4+CD25+ regulatory T-cells in children who have OUtgrown cow's milk allergy. J Exp Med 2004; 199:1679-1688. (Pubitemid 38822001)
34. Akdis M, Blaser K. Akdis CA. T regulatory cells in allergy. Chern Immunol Allergy 2006; 91:159-173. Review. (Pubitemid 43097204)
35. Sumi T. Fukushima A. Fukuda K, et al. Thymus-derived CD4+ CD25+ T-cdls suppress the development of murine allergic conjunctivitis. Int Arch Allergy Immunol 2007; 143:276-81. (Pubitemid 47067039)
36. Lin W, Truong N. Grossman WJ, et al. Allergic dysregulation and hyperimmunoglobulinemia E in Foxp3 mutant mice.J Allergy Clin Immunol2005; 116:1106-15. (Pubitemid 41571796)
37. Van Hove CL, Maes T. Joos GF, et al. Prolonged inhaled allergen exposure can induce persistent tolerance. Am J Respir Cell Mol Bioi 2007 ; 36:573-84. (Pubitemid 46676716)
38. Borish L. IL-I0: Evolving concepts. J Allergy Cli Immunol1998; 101:293-297.
39. Scherf W; Burdach S, Hansen G. Reduced expression of transforming growth factor beta 1 exacerbates pathology in an experimental asthma model. Eur J Immunol 2005; 35:198-206. (Pubitemid 40123866)
40. Frossard CPo Hauser C, Eigenmann PA. Antigen-specificsecretory IgA antibodies in the gut are decreased in a mouse model of food allergy. J Allergy Clin Immunol 2004; 114:377-382. (Pubitemid 39119040)
41. BurchellJT, Wikstrom ME, Stumbles PA, et al. Attenuation of allergen-induced Airway Hyperresponsiveness is mediated by airway regulatory T-cdls. Am J Physiol Lung Cell Mol Physiol 2008. (Epub ahead of print)
42. Carson WF 4th, Guernsey LA, Singh A, et al. Accumulation of regulatory T-cdls in local draining lymph nodes of the lung correlates with spontaneous resolution of chronic asthma in a murine model. Int Arch Allergy Immunol 2008; 145:231-43. (Pubitemid 351301315)
43. Ostroukhova M. Seguin-Devaux C, Oriss TB, et al. Tolerance induced by inhaled antigen involvesCD4+ T-cells expressing membrane-bound TGF-beta and FOXP3. J Clin Invest 2004; 114:28-38. (Pubitemid 39071641)
44. Stock P. DeKruyff RH, Umetsu DT. Inhibition of the allergic response by regulatory Tscells. Curr Opin Allergy Clin Immunol2006; 6:12-6. Review. (Pubitemid 44517803)
45. FrancisJN. Till SJ. Durham SR. Induction oflL-10+CD4+CD25+ T-cells by grasspollen immunotherapy. J Allergy Clin Immunol2003; 111:1255-1261.
46. Grindebacke H. Wing K, Andersson AC, et al. Defective suppression ofTh2 cytokines by CD4CD25 regulatory T-cdls in birch allergies during birch pollen season. Clin Exp Allergy 2004; 3:1364-1372. (Pubitemid 39233690)
47. Xu G. Mou Z, Jiang H, et al. A possible role of CD4+CD25+ T-cells as well as transcription factor Foxp3 in the dysregulation of allergic rhinitis. Laryngoscope 2007 ; 117:876-80. (Pubitemid 46699362)
48. Lee JH. Yu HH. Wang LC, et al. The levels of CD4+CD25+ regulatory T-cells in paediatric patients with allergic rhin itis and bronchial asthma. Clin Exp Immunol2007; 148:53-63.
49. Thunberg S, Akdis M, Akdis CA, et al. Immune regulation by CD4+CD25+ T-cells and inrerleukin-Hl in birch pollen-allergic patients and non-allergic controls Clin Exp Allergy 2007; 37:1127-1136. (Pubitemid 47076340)
50. Maggi L. Santaria sci V. Liotta F, et al. Demonstration o f circulating allergen-specific CD4+CD25highFoxp3+ T-regulatory cells in both nonatopic and atopic individuals J Allergy Clin Immunol 2007: 120:429-436. (Pubitemid 47411530)
51. Nagato T, Kobayashi H. Yanai M, et al. Functional analysis of birch pollen allergen Bet v I-specific regulatory T-cdls. J Immunol 2007; 178:1189-1198. (Pubitemid 46095193)
52. Winkler B, Hufnagl K. Spittler A, et al. The role of Foxp3+ T-cdls in long-term efficacyof prophylactic and therapeutic mucosal tolerance induction in mice. Allergy 2006: 61:173-80. (Pubitemid 43381826)
53. Wilson MS. Taylor MD, BalicA, et al. Suppression of allergic airway inflammation by helminth- induced regulator y T-cells. J Exp Med 2005; 202:1199-212. (Pubitemid 41586951)
54. Flohr C. ~innell RJ. Britton J. Do helminth parasites prote ct against atopy and allergic disease? Clin Exp Allergy 2009; 39:20-32.
55. Schaub B. Liu J. Heppler S, et al. Impairment of T-regulatory cells in cord blood of atopic mothers. J Allergy Clin Immunol 2008; 121:1491-9.
56. Smith M. Touriguy MR, Noakes P, et al. Children with egg allergy have evidence of reduced neonatal CD4+CD25+CDI27101- regulatory T-cell function. J Allergy Clin Immunol 2008; 121:1460-6.
57. Schaub B. Campo M. He H, et al. Neonatal immune responses to TLR2 stimulation: Influence of maternal atopy on Foxp3 and IL-IO expression. Respir Res 2006; 21:7:40-48.
58. Reefer AJ. Satinover SM. Solga MD, et al. Analysis of CD25hiCD4+ "regulato ry" T-cell subtypes in atopic dermatitis reveals a novel TH2-like population. J Allergy Clin Immunol 2008; 121:415-422.
59. Caproni M. Antiga E, Torchia D, et al. FoxP3-expressingT regulatory cells in atopic dermatitis lesions. Allergy Asthma Proc 2007; 28:525-528.
60. de Boer OJ, van der Loos CM, TeelingP, et al. Immunohistochemical analysis of regulatory T-cell markers FOXP3 and GITR on CD4+CD25 +T-cells in normal skin and inflammatory dermatoses. J Histochem Cytochem 2007; 55:891-898. (Pubitemid 47293835)
61. O'Garra A. Barrat FJ. Castro AG, et al. Strategies for use of IL-I0 or its antagonists in human disease. Immunol Rev 2008; 223:114-131. (Pubitemid 351986180)
62. Xystrakis E. Kusumakar S. Boswell S, et al. Reversing the defective induction ofIL-IO-secreting regulatory T-cells in glucocorticoid-resistant asthma patients J Clin Invest 2006 ; 116:146-155. (Pubitemid 43121799)
63. Hard D. Koller B, Mehlhorn AT, et al. ~antitative and functional impairment of pulmonary CD4+CD25hi regulatory 'l-cells in pediatr ic asthma. J Allergy Clin Immunol2007; 119:1258-66.
64. Durham SR. Allergen immunotherapy (desensitisation ) for allergic diseases. Clin Med 2006; 6:348-351. (Pubitemid 44298793)
65. Nelson HS. Advances in uppet alrway diseases and allergen immunotherapy. J Allergy Clin Immunol 2007; 119:872-880. (Pubitemid 46527809)
66. Noon L. Prophylactic inoculat ion against hay fever. Lancet 1911; 1:1572-1573.
67. Frew AJ. Powell RJ. Corrigan CJ, et al. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjun ctivit is. J Allergy Clin Immunol 2006; 117:319-325 (Pubitemid 43190146)
68. Walker SM. Pajno GB, Lima MT, et al. Grass pollen immunotherapy for seasonal rhinitis and asthma: A randomized , controlled trial. J Allergy Clin Immunol2001; 107:87-93. (Pubitemid 32105250)
69. Akdls CA. Blesken T. Akdis M, et al. Role of inrerleukin 10 in specific immunotherapy. J Clin Invest 1998; 102:98-106.
70. Durham SR. Walker SM. VargaEM, et al. Long-Term Clinical Efficacy of Grass-Pollen Immunotherapy. New Engl J Med 1999; 341:468-475. (Pubitemid 29372886)
71. Wachholz PA. Noun-Aria KT. Wilson DR, et al. Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral ThI :Th2 cytokine ratios. Immunolog y 2002; 105:56-62. (Pubitemid 34128040)
72. Till SJ. FrancisIN. Nouri-Aria K, et al. Mechanisms of immunotherapy. J Allergy Clin Immunol 2004; 113:1025-1034. Review. (Pubitemid 38857978)
73. Robinson DS. Larche M. Durham SR. Tregs and allergic disease. J Clin Invest 2004; 114:1389-1397. Review. (Pubitemid 40385566)
74. Verhagen J. Taylor A. Blaser K, et al. T regulatory cells in allergen-specific immunotherapy. Int Rev Immunol 2005; 24:533-548. Review. (Pubitemid 41755159)
75. Ajduk J. Marinic I. Aberle N, et al. Effect of house dust mite immunotherapy on transforming growth factor beta I-producing T-cells in asthmatic children. Ann Allergy Asthma Immunol 2008; 100:314-22. (Pubitemid 351520321)
76. Mekala DJ. AlIi RS. Geiger TL. IL-IO-dependent infectious tolerance alter the treatment of experimental allergic encephalomyelitis with redirected CD4+CD25+ T-Iymphocytes. Proc Nad Acad Sci USA 2005; 102:11817-11822. (Pubitemid 41170808)
77. Akdis CA. Joss A. Akdis M, et al. A molecular basis for T-cell suppression by IL-I0: CD28-associated IL-I0 receptor inhibits CD28 tyrosine phosphorylation and phosphat idylinositol 3-kinase binding. FASEBJ 2000; 14:1666-1668
78. Noun-Aria KT, Wachholz PA. Francis IN, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-I0 responses and blocking IgG activity. J Immunol 2004; 172:3252-3259. (Pubitemid 38263717)
79. Pilette C, Nouri-AriaKT.JacobsonMR, et al. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associatedwith mucosal TGF-beta expression. J Immunol 2007; 178:4658-4666. (Pubitemid 46492419)
80. jutel M, Akdis M. Budak F, et al. IL-IO and TGF-beta cooperate in the regulatory T-cell response to mucosal allergens in normal immunity and speci fic immunotherapy. Eur J Immunol 2003 ; 33:1205-1214. (Pubitemid 36609138)
81. Radulovic S, Jacobson MR. Durham SR, et al. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol 2008: 121:1267-1272.
82. Motter C. Uhlig HH. Powrie F. Cutting edge: Cure of colitis by CD4+CD25+ regulatory T-cells. J Immunol 2003: 170:3939-3943. (Pubitemid 36428153)
83. Pereira-Santos MC. Baptista AP. Melo A, et al. Expansion of circulating Foxp3+CD25b,;gh, CD4+ T-cells during specific venom immunotherapy. Clin Exp Allergy 2008; 38:291-297.
84. Akdis CA. Akdis M. Blesken T, et al. Epuope-spedfic T-cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by lL-2 and IL-15 in vitro. J Clin Invest 1996: 98:1676-1683 (Pubitemid 26327879)
85. Taylor A. Verhagen J. Blaser K, et al. Mechanisms of immune suppression by interleukin-If) and transforming growth factor-beta : The role ofT regulatory cells. Immunology 2006: 117:433-442.
86. Croxford JL. Feldmann M, Chernajovsky Y, et al. Different therapeutic outcomes in experimental allergic encephalomyelitis dependent upon the mode of delivery of IL-I0: A comparison of the effects of protein. Adenoviral or retroviral IL-I0 delivery into the central nervous system. J Immunol 2001; 166:4124-4130. (Pubitemid 32224944)
87. Hansen G, Yeungvp. Berry G, et al. Vaccination with heat-killed Listeria as adjuvant reversesestablished allergen-induced airway hyperreactivity and inflammation : Role of CD8+ 'f-cells and IL-18. J Immunol 2000: 164:223-230. (Pubitemid 30012994)
88. Crericos PS. Schroeder JT, Hamilton RG. Immune Tolerance Network Group. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis N Engl J Med 2006; 355:1445-1455. (Pubitemid 44511559)
89. Van Overtvelt L, Lombardi V, Razafindratsita A, et al. IL-lO-inducing adjuvants enhance sublingual immunotherapy efficacyin a murine asthma model. Int Arch Allergy Immunol 2008; 145:152-62.